Rigaku Corporation, a Rigaku Holdings Group company and global partner for X-ray analysis from lab to factory, has developed and is patenting a technology called “Electron Density Topology” (EDT) that can clarify the structural and dynamic characteristics of biomacromolecules in solution, including antibodies, protein complexes, and virus particles.
EDT enables direct observation of biomacromolecules in solution, reducing artifacts caused by measurement conditions. EDT is expected to improve the development process of innovative biopharmaceuticals, including monoclonal antibody-based therapies and advanced drug delivery systems.
Also Read: Moffitt Partners with AstraZeneca to Boost Oncology Cell Therapies
EDT provides information about the overall shape, molecular characteristics and internal structure of biomacromolecules by determining the electron distribution of the molecular chemical properties. In addition, EDT can directly observe the electron density of biomacromolecules without prior knowledge of the sample.
In the process of drug development, in order to optimize resources, it is necessary to determine whether the drug has the expected structure and ideal properties at an early stage. EDT technology can meet this requirement and is expected to be used in the basic research and development of biopharmaceuticals such as antibody drugs.
Rigaku Group‘s professional engineers have been committed to using cutting-edge technology to benefit society, especially in its core fields of X-ray and thermal analysis. With a market presence in more than 90 countries and approximately 2,000 employees in 9 countries around the world, Rigaku is a solution partner for industry and research and analysis organizations.
SOURCE: Businesswire